FDA elevates tomato recall to highest risk level over potential salmonella contamination
Williams Farms Repack LLC issued a recall for some of its tomatoes back on May 2. On May 28, the FDA assigned the recall a Class I designation, which indicates that use of the recalled product could cause "serious adverse health consequences or death."
The recall includes "4x5 2 layer," "60ct 2-layer" and three-count trays of Williams Farms Repack label tomatoes, according to a company announcement shared on the FDA website. The recall also impacts "5x6" and "6x6" 25-pound boxes of H&C Farms Label tomatoes, the company said.
All recalled tomatoes have lot codes of R4467 or R4470. The three-pack tomatoes bear the UPC number 0 33383 65504 8.
Tomatoes sold in 11 states voluntarily recalled due to potential salmonella contamination
For a full list of recalled products, click here.
The recalled tomatoes were previously distributed between April 23 and 28 in Georgia, North Carolina, and South Carolina, the company said in its recall announcement.
"On April 29, 2025, the firm was notified via telephone by Southeast Tomato Distributors that tomatoes supplied from H&C Farms may be contaminated with Salmonella," it stated at the time. "No illnesses have been reported to date."
Salmonella are bacteria that cause about 1.35 million infections in the U.S. every year, with contaminated food as the source for most of these illnesses, according to the U.S. Centers for Disease Control and Prevention.
The agency states that salmonella is most often spread through food but can also spread through water, animals, people and other ways.
Salmonella outbreak linked to cucumbers sold to restaurants sickens 26 people, health officials warn
According to the CDC, symptoms of a salmonella infection include abdominal pain, fever, headache, watery diarrhea that may also have blood or mucus, loss of appetite, nausea and vomiting, and usually start six hours to six days after infection, typically lasting four to seven days.
Anyone in possession of the recalled tomatoes is urged not to eat them and to discard them or return them to their place of purchase for a full refund.
ABC News has reached out to Williams Farms Repack LLC for comment.
FDA elevates tomato recall to highest risk level over potential salmonella contamination originally appeared on goodmorningamerica.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Epoch Times
27 minutes ago
- Epoch Times
Malfunctioning Insulin Pumps Recalled After 59 Injuries
San Diego-based Tandem Diabetes Care, Inc. is voluntarily recalling insulin pumps used to manage blood sugar, the company said in an Aug. 12 announcement by the Food and Drug Administration. Insulin pumps are wearable devices that deliver insulin at predetermined doses at specific times. Such devices can feature alarm functions to alert users about various situations, such as issues with insulin delivery.


The Hill
5 hours ago
- The Hill
Senate Democrat rips Costco for ‘refusing to sell' abortion pills
Sen. Patty Murray (D-Wash.) hammered Costco on Friday for appeasing 'far-right extremists,' after the retailer said earlier this week that its pharmacies would not dispense the abortion medication mifepristone. 'I am deeply alarmed by news reports that Costco is refusing to sell safe, effective, and legal medication for no other reason than to appease the politics of anti-abortion fanatics,' Murray said in a statement following the news. 'I refuse to stand by and allow far-right extremists to bully major corporations and dictate what medicine women can or cannot get access to.' 'Where it is legal, retailers and major pharmacies must absolutely make medication abortion available to the women who need it,' the Washington Democrat added. Costco, in its Thursday announcement, explained that the decision came from a 'lack of demand.' 'Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,' the company said, according to Reuters. The decision comes after CVS and Walgreens announced last year that they received certification to provide the drug in states where abortion remains legal. Murray pressed Costco to rescind its decision, warning that limiting access to mifepristone, one of two drugs used in medication abortion, is harmful to women's health. 'Mifepristone is safe and effective—we cannot live in a world where the availability of women's health care whipsaws back and forth based on the whims of extremists who want to deny women access to basic health care,' she wrote Friday. 'I am demanding that Costco immediately reverse course—follow the science and the facts, not the demands of far-right anti-abortion extremists.' The Supreme Court in a decision last year ruled unanimously that a group of anti-abortion doctors did not have the legal basis to challenge access to the pill. Despite the ruling, Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary are weighing a review of the abortion pill. Murray questioned Makary during his Senate confirmation hearing on the proposal, as well as President Trump's moves to gut staff at the FDA.
Yahoo
8 hours ago
- Yahoo
Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Precigen and Pfizer, as well as updates from the Institute for Clinical and Economic Review, Superluminal Medicines and Generation Bio that you may have missed. The Food and Drug Administration granted full approval to a first-of-its-kind treatment for recurrent respiratory papillomatosis, a rare and potentially life-threatening condition caused by persistent HPV infections. Thursday's clearance of Precigen's Papzimeos, an immunotherapy that helps clear HPV-infected cells, was based on study results showing a little more than half of drug recipients didn't need surgery within a year of therapy. Center for Biologics Evaluation and Research director Vinay Prasad, who rejoined the FDA this week, described the approval as proof 'randomized trials are not always needed to approve medical products.' That statement should be 'reassuring' to biotech investors concerned about stricter regulatory standards under Prasad, wrote Cantor Fitzgerald analyst Jennifer Kim. Precigen shares rose higher Friday on the news. — Ben Fidler An experimental Pfizer drug for sickle cell disease failed to meet its goal in a Phase 3 study, the company said Friday. Testing showed that treatment with inclacumab, a drug Pfizer acquired via its 2022 buyout of Global Blood Therapeutics, failed to significantly reduce versus placebo the pain crises people with sickle cell often experience. Pfizer said it would share analyses of the data with the scientific and patient community in 'due course.' Last year, the company pulled from market another sickle cell drug, Oxbryta, that it gained from Global Blood, citing safety concerns. The company plans to provide updates on Oxbryta and a third Global Blood drug, the experimental osivelotor, when they become available. — Ned Pagliarulo Eli Lilly will collaborate with biotechnology startup Superluminal Medicines to develop new drugs for cardiometabolic diseases and obesity. Through the alliance, the two intend to discover and advance small molecule medicines aimed at undisclosed G protein-coupled receptor, or GPCR, targets 'relevant' to those conditions. Lilly will receive exclusive rights to the compounds emerging from the deal, while Superluminal could get up to $1.3 billion in total payouts, including an unspecified upfront payment as well as an equity investment, the companies said Thursday. — Ben Fidler Autolus Therapeutics is delaying launching its leukemia cell therapy Aucatzyl in Europe following approval there as the company 'evaluates potential pricing and feasibility of market entry opportunities' in some countries. Launch in Germany is on hold and Autolus 'does not anticipate any EU sales of Aucatzyl in 2025 and 2026,' the company said in its second quarter earnings report. In the U.K., where Aucatzyl has also been approved, a government cost-effectiveness monitor has initially decided not to pay for it. Autolus said it 'will continue to work towards a pathway for patient access to therapy in the U.K.' Approved by the Food and Drug Administration in November 2024, Aucatzyl earned just shy of $30 million in sales in the first six months of 2025, all from the U.S. — Jonathan Gardner Generation Bio revealed preclinical results suggesting a delivery technology it's developing can effectively send nucleic acid payloads into T cells. But the company also said this week that it may not be able to raise the funds to prove that approach works in humans and, as a result, began a strategic review that could end in a sale or merger. Generation will lay off roughly 90% of its workforce, including all of its research and development staff, by the end of October. Company shares climbed 60%, though they've lost much of their value since the company's initial public offering in 2020. — Ben Fidler Recommended Reading Eli Lilly's Julie Gilmore on finding up-and-coming companies and backing small biotechs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data